Graves Lara E, Donaghue Kim C
Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Hawkesbury Road, and Hainsworth Street, Westmead, NSW, 2145, Australia.
Institute of Endocrinology and Diabetes, The Children's Hospital at Westmead, Westmead, NSW, Australia.
Ther Adv Endocrinol Metab. 2019 Jul 25;10:2042018819863226. doi: 10.1177/2042018819863226. eCollection 2019.
Type 1 and type 2 diabetes are increasing in prevalence and diabetes complications are common. Diabetes complications are rarely studied in youth, despite the potential onset in childhood. Microvascular complications of diabetes include retinopathy, diabetic kidney disease or nephropathy, and neuropathy that may be somatic or autonomic. Macrovascular disease is the leading cause of death in patients with type 1 diabetes. Strict glycaemic control will reduce microvascular and macrovascular complications; however, they may still manifest in youth. This article discusses the diagnosis and treatment of complications that arise from type 1 and type 2 diabetes mellitus in youth. Screening for complications is paramount as early intervention improves outcome. Screening should commence from 11 years of age depending on the duration of type 1 diabetes or at diagnosis for patients with type 2 diabetes. Diabetic retinopathy may require invasive treatment such as laser therapy or intravitreal antivascular endothelial growth factor therapy to prevent future blindness. Hypertension and albuminuria may herald diabetic nephropathy and require management with angiotensin converting enzyme (ACE) inhibition. In addition to hypertension, dyslipidaemia must be treated to reduce macrovascular complications. Interventional trials aimed at examining the treatment of diabetes complications in youth are few. Statins, ACE inhibitors and metformin have been successfully trialled in adolescents with type 1 diabetes with positive effects on lipid profile, microalbuminuria and measures of vascular health. Although relatively rare, complications do occur in youth and further research into effective treatment for diabetes complications, particularly therapeutics in children in addition to prevention strategies is required.
1型和2型糖尿病的患病率正在上升,糖尿病并发症很常见。尽管糖尿病并发症可能在儿童期就已发病,但针对青少年糖尿病并发症的研究却很少。糖尿病的微血管并发症包括视网膜病变、糖尿病肾病或肾病,以及可能是躯体性或自主性的神经病变。大血管疾病是1型糖尿病患者的主要死因。严格的血糖控制将减少微血管和大血管并发症;然而,这些并发症在青少年中仍可能出现。本文讨论了青少年1型和2型糖尿病所引发并发症的诊断和治疗。由于早期干预可改善预后,因此对并发症进行筛查至关重要。根据1型糖尿病的病程,筛查应从11岁开始,对于2型糖尿病患者则在诊断时开始。糖尿病视网膜病变可能需要激光治疗或玻璃体内抗血管内皮生长因子治疗等侵入性治疗,以预防未来失明。高血压和蛋白尿可能预示着糖尿病肾病,需要使用血管紧张素转换酶(ACE)抑制剂进行治疗。除高血压外,还必须治疗血脂异常以减少大血管并发症。针对青少年糖尿病并发症治疗的干预性试验很少。他汀类药物、ACE抑制剂和二甲双胍已在1型糖尿病青少年中成功进行试验,对血脂谱、微量白蛋白尿和血管健康指标有积极影响。尽管相对罕见,但并发症确实会在青少年中出现,因此需要进一步研究糖尿病并发症的有效治疗方法,特别是针对儿童的治疗方法以及预防策略。